
Sign up to save your podcasts
Or


Every year, scores of new, innovative and expensive prescription medications advance from the drug development pipeline into the marketplace. Which ones have the greatest potential to make a meaningful impact for patients and plan sponsors?
On the latest episode of the Pharmacy Insights Podcast, Optum Rx Senior Vice President of Clinical Consulting Scott Draeger dives into to the latest drug pipeline developments with Sara Guidry, Optum Rx Senior Director of Pipeline and Drug Surveillance and Arash Sadeghi, Optum Rx Clinical Pharmacist for Pipeline and Drug Surveillance. Touching on everything from cancer to Alzheimer’s, together they sift through the noise to identify the new drugs most likely to fill unmet medical needs and create potential financial implications for sponsors of the pharmacy benefit.
The use of artificial intelligence has exploded into the public consciousness in recent years. While people are becoming more accustomed to the presence of AI in their personal lives, what does it mean for pharmacy care services?
On the latest episode of the Pharmacy Insights Podcast, Optum Rx Senior Vice President of Clinical Consulting Scott Draeger welcomed Santiago Abraham, Chief Information Officer at Optum Rx and Sid Sahni, Senior Vice President of Strategy and Innovation at Optum Rx to discuss how Optum Rx is approaching the use of AI and what that means for sponsors and users of pharmacy benefits.
As we exit the first quarter of the 21st century, what are the big trends defining prescription drugs and how pharmacy benefits are administered? On the latest episode of the Pharmacy Insights Podcast, Optum Rx Senior Vice President of Clinical Consulting Scott Draeger welcomed Dr. John Wig, Chief Clinical Officer of Optum Rx, to discuss everything from new indications for GLP-1 medications to emerging biosimilar options for popular biologic drugs to the role of artificial intelligence in pharmacy care.
On this episode of the Pharmacy Insights podcast, host Scott Draeger welcomes Optum Rx SVP of Industry Relations, Jamey Millar and Optum Rx SVP of formulary management, Savitha Vivian to discuss the implications of new biosimilar alternatives to expensive biologic drugs.
From the publisher's feed

56,472 Listeners

369,666 Listeners

402 Listeners